Sign in
Not yet taking people in NetherlandsPhase 2

Adding ritonavir to ibrutinib in chronic lymphocytic leukemia and two types of lymphoma

Tests ritonavir added to ibrutinib in adults with chronic lymphocytic leukemia or lymphoma.

Key facts

Who runs it
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Where
's-Gravenhage, 'S-Hertogenbosch, Almelo, Amersfoort, Amstelveen, Amsterdam, Apeldoorn, Breda, Doetichem, Emmen, Goes, Gouda, Groningen, Hoofddorp, Hoorn Nh, Leeuwarden, Nieuwegein, Rotterdam, Tilburg, Venlo, Zaandam, and Zwolle, NetherlandsSee the 24 sites
Registry title
Addition of ritonavir to ibrutinib treatment in patients with chronic leukemia and certain types of lymphoma
Status
Not yet recruiting
Phase
Phase 2
People taking part
177 people, planned
Started
2 Nov 2026
Expected to end
2 Nov 2029
Type of study
Interventional
Record updated
12 October 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with chronic lymphocytic leukemia, lymphoplasmacytic lymphoma or mantle cell lymphoma who already take ibrutinib. It tests adding ritonavir to ibrutinib.

Age
18 years or older.
Sex
The record lists males only.
Disease stage
Chronic lymphocytic leukemia (CLL), lymphoplasmacytic lymphoma (LPL) or mantle cell lymphoma (MCL), diagnosed by the World Health Organization classification (WHO 2024). Physical fitness score (WHO PS) 0, 1 or 2.
Earlier treatment
Must have taken ibrutinib for more than 60 days without any dose reduction.

Main reasons for not taking part

  • Another cancer now or before, unless treatment ended at least 24 months before registration (skin and cervical in situ cancers excepted)
  • Chemotherapy, radiation or immunotherapy at the same time
  • Strong inhibitors or inducers of certain liver enzymes (CYP3A, CYP2D6, UGT, P gp) that must be used
  • Severe or uncontrolled illness, or an infection needing treatment
  • Heart attack within 3 months, severe heart failure or unstable heart rhythm

The registry criteria, word for word

Show all 22 criteriaShow less

Who can take part

  • ≥ 18 years
  • Patients with a diagnosis of chronic lymphocytic leukemia (CLL), lymphoplasmacytic lymphoma (LPL) or mantle cell lymphoma (MCL) according to the World Health Organization classification (WHO 2024)
  • Patients receiving ibrutinib > 60 days at the time of inclusion without any dose-reduction
  • World Health Organization performance status (WHO PS) 0, 1 or 2
  • Adequate renal and hepatic functions as indicated by the laboratory values described in the protocol unless clearly disease related
  • Patient is able and willing to adhere to the study visit schedule and other protocol requirements
  • Patient is capable of giving informed consent
  • Written informed consent

Who cannot take part

  • Diagnosis of any previous or concomitant malignancy: – except when the patient successfully completed treatment (chemotherapy and/or surgery and/or radiotherapy) with curative intent for this malignancy at least 24 months prior to registration, – except for basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix,
  • Current concomitant chemotherapy, radiation therapy, or immunotherapy
  • Participation in another interventional clinical study at the time of inclusion or during protocol treatment without prior approval
  • Essential use of strong inhibitors or inducers of Cytochrome P450 3A (CYP3A), Cytochrome P450 2D6 (CYP2D6), Uridine Diphosphate glucuronosyltransferase (UGT) or P glycoprotein (P gp) or substrates of the aforementioned enzymes with a narrow therapeutic window
  • Concurrent severe and/or uncontrolled medical condition (e.g. uncontrolled: infection, autoimmune hemolysis, immune thrombocytopenia, diabetes, hypertension, hyperthyroidism or hypothyroidism etc.)
  • Ongoing active bacterial, viral, fungal, mycobacterial, parasitic or other infection requiring systemic treatment (excluding prophylactic treatment) at the time of enrollment or within the previous 2 weeks prior to Cycle 1 Day 1 (C1D1)
  • History of stroke or intracranial hemorrhage within 6 months prior to registration
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
  • Intolerability, contra-indication or allergy to one of the study drugs
  • Cardiac dysfunction as defined by: – Myocardial infarction within the last 3 months of study registration, – Heart failure (NYHA) grade IV), – Unstable cardiac arrhythmias
  • History of non-compliance to medical regimens or considered unreliable with respect to compliance
  • Senile dementia, mental impairment or any other psychiatric disorder that prohibits the patient from understanding and giving informed consent
  • Fertile men or women of childbearing potential (WOCBP) unless: (1) surgically sterile or ≥ 2 years after the onset of menopause; (2) willing to use a highly effective contraceptive method during study treatment and until 3 months after ibrutinib treatment
  • Symptomatic central nervous system (CNS) involvement

Where in Netherlands

  • Haga Hospital's-Gravenhage, NetherlandsNot yet recruiting
  • Jeroen Bosch Ziekenhuis Stichting'S-Hertogenbosch, NetherlandsNot yet recruiting
  • Ziekenhuisgroep Twente StichtingAlmelo, NetherlandsNot yet recruiting
  • Meander Medisch CentrumAmersfoort, NetherlandsNot yet recruiting
  • Ziekenhuis AmstellandAmstelveen, NetherlandsNot yet recruiting
  • Amsterdam UMC StichtingAmsterdam, NetherlandsNot yet recruiting
  • Stichting OLVGAmsterdam, NetherlandsNot yet recruiting
  • Gelre HospitalsApeldoorn, NetherlandsNot yet recruiting
  • Amphia HospitalBreda, NetherlandsNot yet recruiting
  • Slingeland HospitalDoetichem, NetherlandsNot yet recruiting
  • Treant Ziekenhuiszorg StichtingEmmen, NetherlandsNot yet recruiting
  • Admiraal De Ruyter Ziekenhuis B.V.Goes, NetherlandsNot yet recruiting
  • Groene Hart ZiekenhuisGouda, NetherlandsNot yet recruiting
  • Martini Ziekenhuis StichtingGroningen, NetherlandsNot yet recruiting
  • Universitair Medisch Centrum GroningenGroningen, NetherlandsNot yet recruiting
  • Spaarne Gasthuis StichtingHoofddorp, NetherlandsNot yet recruiting
  • Dijklander ZiekenhuisHoorn Nh, NetherlandsNot yet recruiting
  • Frisius MCLeeuwarden, NetherlandsNot yet recruiting
  • St. Antonius ZiekenhuisNieuwegein, NetherlandsNot yet recruiting
  • Ikazia ZiekenhuisRotterdam, NetherlandsNot yet recruiting
  • Stichting Elisabeth-TweeSteden ZiekenhuisTilburg, NetherlandsNot yet recruiting
  • Stichting Viecuri Medisch Centrum voor Noord-LimburgVenlo, NetherlandsNot yet recruiting
  • Zaans Medisch Centrum StichtingZaandam, NetherlandsNot yet recruiting
  • Isala Klinieken StichtingZwolle, NetherlandsNot yet recruiting

About the trial

What the trial wants to find out

Run-in phase: To demonstrate that ritonavir-boosted low-dose ibrutinib provides adequate systemic exposure relative to standard-dose ibrutinib. Extension phase: To assess the toxicity of a defined schedule of ritonavir added to ibrutinib in adult patients with chronic lymphocytic leukemia (CLL), lymphoplasmacytic lymphoma (LPL), and mantle cell lymphoma (MCL)

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
HOVON 185: Pharmacokinetic boosting of ibrutinib with ritonavir in patients with chronic lymphocytic leukemia, lymphoplasmacytic- and mantle cell lymphoma
Plain-language title
Adding ritonavir to ibrutinib in chronic lymphocytic leukemia and two types of lymphomaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
12 October 2026